Related Experiment Video
Updated: Jul 6, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
Takayasu's arteritis
Curry L Koening1, Carol A Langford
1University of Utah, Division of Rheumatology, Room 4b200 SOM, 1900 East 30 North, Salt Lake City, UT 84132, USA. Curry.Koening@hsc.utah.edu
Takayasu's arteritis, a rare inflammatory condition, primarily affects young women, impacting the aorta and its branches. Management involves immunosuppression, with surgery reserved for severe cases.
Area of Science:
- Vascular Inflammation
- Autoimmune Diseases
- Rheumatology
Background:
- Takayasu's arteritis is a rare, chronic inflammatory condition affecting large arteries, predominantly the aorta and its branches.
- It primarily impacts young females, leading to stenosis or aneurysms and potential organ ischemia.
- Clinical manifestations include stroke, claudication, absent pulses, and asymmetric blood pressures.
Purpose of the Study:
- To summarize the current understanding of Takayasu's arteritis.
- To outline diagnostic and therapeutic strategies.
- To emphasize monitoring and long-term management.
Main Methods:
- Review of existing literature on Takayasu's arteritis.
- Description of clinical presentation and diagnostic findings.
- Overview of current treatment modalities, including medical and surgical interventions.
Main Results:
- Chronic immunosuppressive therapy, primarily with glucocorticoids and other agents, is the mainstay of treatment.
- Tumor necrosis factor inhibitors show promise in refractory cases.
- Revascularization via bypass grafting is preferred over angioplasty for severe ischemia due to lower restenosis rates.
Conclusions:
- Effective management requires a combination of immunosuppression, vigilant monitoring for relapse and toxicity, and timely revascularization.
- Regular clinical evaluation and imaging are crucial for assessing disease activity and treatment response.
- Long-term remission is defined by the absence of new lesions, systemic symptoms, and low-dose steroid use.
Related Concept Videos
Pericarditis I: Introduction
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Pericarditis III: Medical Management
Pericarditis II: Clinical Features and Diagnostic Tests